NCT04523064CompletedPhase 4
POST-CABGDM: Empagliflozin in Perioperative CABG
Empagliflozin for Prevention of Acute Kidney Injury in Patients With Type 2 Diabetes Mellitus Undergoing Extracorporeal On-pump CABG: The POST-CABGDM Trial
Source: ClinicalTrials.gov · Last updated 10 Jun 2024
Brief summary (registry, in English)
Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished. The revascularization surgery is commonly indicated to patients with multivessel coronary disease and kidney injury is a prevalent complication in post operation. This work aims to evaluate the impact of a strategy to control Diabetes Mellitus using inhibitors of sodium-glucose cotransporters (ISGLT2) in diabetics patients with assigned myocardial revascularization with cardiopulmonary bypass
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 155 (actual)
- First submitted
- 18 Aug 2020
- Start date
- 22 Sept 2020
- Primary completion date
- 30 Jan 2024
- Lead sponsor
- University of Sao Paulo General Hospital
- Diseases
- Coronary artery disease, Type 2 diabetes
- NCT number
- NCT04523064
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 155
- From 22 Sept 2020 to the primary completion date, 30 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Terminal or disabling illness with reduced life expectancy;
Lab values
- eGFR \<30mL / min / 1.73m2 or dialysis therapy;
Other
- Inability to sign the informed consent form;
- Contraindication to CABG on pump;
- Need for urgent or emergency CABG;
- Pregnancy in progress.
Who the study is looking for
- Age \> 18
- Type 2 diabetes mellitus
- Multivessel CAD documented by coronary angiography with formal indication for CRM.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Sao Paulo Medical School - The Heart Institute Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.